

Supplemental Table 1. Details of study design and participation by study

Study	Study period (Recruitment)	Age range	Glioma Cases (n)	Case response rate for blood collection	Controls (n)	Control response rate for blood collection	Cases with GWAS	Controls with GWAS	Total genotyped	Total with GWAS	% with available DNA SNPs (Based on Cases & Controls)
Case-control											
NCI	1994-1998	18+	386	87%	473	75%	351	422	859	773	89.99
NIOSH	1995-1997	18-80	324	73%	565	72%	305	542	889	847	95.28
Cohorts											
PLCO	1993-2001	55-74	157	58%	868	*	140	857	1025	997	97.27
ATBC	1985-1988	50-69 yrs	39	70%	1271	*	37	1270	1310	1307	99.77
AHS	1993-1997	30-64 yrs	21		42		18	35	63	53	84.13
TOTAL			927		3219		851	3126	4146	3977	95.92

*Controls from PLCO and ATBC are individuals without Glioma for whom genome-wide scans were previously completed.

NCI=National Cancer Institute glioma case-control study.

NIOSH=National Institute of Occupational Safety and Health glioma case-control study.

PLCO= Glioma cases and controls identified from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

ATBC= Glioma cases and controls identified from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.

AHS= Glioma cases and controls identified from the Agricultural Health Study.